These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

6205 related items for PubMed ID: 19322513

  • 1. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E, Minuto F, Colao A, Ferone D.
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [Abstract] [Full Text] [Related]

  • 2. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S, Gasco V, Ragazzoni F, Ghigo E.
    J Endocrinol Invest; 2003 Jun; 26(10 Suppl):27-35. PubMed ID: 15497657
    [Abstract] [Full Text] [Related]

  • 3. [Evaluation of leptin levels in plasma and their reliance on other hormonal factors affecting tissue fat levels in people with various levels of endogenous cotisol].
    Robaczyk MG.
    Ann Acad Med Stetin; 2002 Jun; 48():283-300. PubMed ID: 14601484
    [Abstract] [Full Text] [Related]

  • 4. Homocysteine levels in acromegaly patients.
    Hekimsoy Z, Ozmen B, Ulusoy S.
    Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
    [Abstract] [Full Text] [Related]

  • 5. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC, Schwartz S, Rosenberg MA, Jariwala N, Becker RH, Johnston PS.
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR.
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [Abstract] [Full Text] [Related]

  • 7. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
    Bastemir M, Akin F, Yaylali GF.
    Neuroendocrinology; 2007 Feb; 86(2):119-23. PubMed ID: 17671378
    [Abstract] [Full Text] [Related]

  • 8. Low serum IGF-I/GH ratio is associated with abnormal glucose tolerance in acromegaly.
    Fukuoka H, Takahashi Y, Iida K, Kudo T, Nishizawa H, Imanaka M, Takeno R, Iguchi G, Takahashi K, Okimura Y, Kaji H, Chihara K.
    Horm Res; 2008 Feb; 69(3):165-71. PubMed ID: 18219220
    [Abstract] [Full Text] [Related]

  • 9. Insulin sensitivity in growth hormone (GH)-deficient adults and effect of GH replacement therapy.
    Alford FP, Hew FL, Christopher MC, Rantzau C.
    J Endocrinol Invest; 1999 Feb; 22(5 Suppl):28-32. PubMed ID: 10442567
    [Abstract] [Full Text] [Related]

  • 10. Type II diabetes and syndrome X. Pathogenesis and glycemic management.
    Karam JH.
    Endocrinol Metab Clin North Am; 1992 Jun; 21(2):329-50. PubMed ID: 1612069
    [Abstract] [Full Text] [Related]

  • 11. Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance.
    Eriksson JG, Lehtovirta M, Ehrnström B, Salmela S, Groop L.
    J Intern Med; 2006 Jun; 259(6):553-60. PubMed ID: 16704555
    [Abstract] [Full Text] [Related]

  • 12. Effects of growth hormone on glucose metabolism.
    Møller N, Jørgensen JO, Abildgård N, Orskov L, Schmitz O, Christiansen JS.
    Horm Res; 1991 Jun; 36 Suppl 1():32-5. PubMed ID: 1806481
    [Abstract] [Full Text] [Related]

  • 13. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus.
    Rader DJ.
    Am J Med; 2007 Mar; 120(3 Suppl 1):S12-8. PubMed ID: 17320517
    [Abstract] [Full Text] [Related]

  • 14. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K, Dhillo WS.
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [Abstract] [Full Text] [Related]

  • 15. New therapeutic agents for the treatment of NIDDM.
    Kuehnle HF.
    Exp Clin Endocrinol Diabetes; 1996 Aug; 104(2):93-101. PubMed ID: 8740931
    [Abstract] [Full Text] [Related]

  • 16. On the pathophysiology of late onset non-insulin dependent diabetes mellitus. Current controversies and new insights.
    Vaag A.
    Dan Med Bull; 1999 Jun; 46(3):197-234. PubMed ID: 10421979
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S, Nakamura K, Takeuchi M.
    Med Hypotheses; 2005 Jun; 65(1):152-4. PubMed ID: 15893133
    [Abstract] [Full Text] [Related]

  • 18. [Amylin as an additional possible pathogenic factor in NIDDM and the insulin resistance syndrome].
    Hrnciar J.
    Vnitr Lek; 1996 Aug; 42(8):557-60. PubMed ID: 8967027
    [Abstract] [Full Text] [Related]

  • 19. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control.
    Ahn CW, Kim CS, Nam JH, Kim HJ, Nam JS, Park JS, Kang ES, Cha BS, Lim SK, Kim KR, Lee HC, Huh KB.
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):444-9. PubMed ID: 16584518
    [Abstract] [Full Text] [Related]

  • 20. [Diabetes secondary to endocrinolopathies].
    Suzuki S.
    Nihon Rinsho; 1996 Oct; 54(10):2709-14. PubMed ID: 8914432
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 311.